Cargando…

The altered expression of neurofilament in mouse models and patients with spinal muscular atrophy

OBJECTIVES: To investigate the levels of neurofilaments (NFs) in transgenic mice and patients with spinal muscular atrophy (SMA), and to evaluate their efficacy as a biomarker in SMA. METHODS: The levels of NF mRNA transcripts were measured by quantitative real‐time PCR in spinal cord from SMA mice....

Descripción completa

Detalles Bibliográficos
Autores principales:	Spicer, Charlotte, Lu, Ching‐Hua, Catapano, Francesco, Scoto, Mariacristina, Zaharieva, Irina, Malaspina, Andrea, Morgan, Jennifer E., Greensmith, Linda, Muntoni, Francesco, Zhou, Haiyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045929/ https://www.ncbi.nlm.nih.gov/pubmed/33683023 http://dx.doi.org/10.1002/acn3.51336

Ejemplares similares

Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
por: Catapano, Francesco, et al.
Publicado: (2016)

Revised Hammersmith Scale for spinal muscular atrophy: Inter and intra-rater reliability and agreement
por: Ramsey, Danielle, et al.
Publicado: (2022)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen
por: Weststrate, Harriet, et al.
Publicado: (2022)

Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment
por: Sintusek, Palittiya, et al.
Publicado: (2016)

Microvasculopathy in spinal muscular atrophy is driven by a reversible autonomous endothelial cell defect
por: Zhou, Haiyan, et al.
Publicado: (2022)

Response of plasma microRNAs to nusinersen treatment in patients with SMA
por: Zaharieva, Irina T., et al.
Publicado: (2022)

Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
por: Zhou, Haiyan, et al.
Publicado: (2020)

Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy
por: Zaharieva, Irina T., et al.
Publicado: (2013)

Correlation of clinical and molecular features in spinal bulbar muscular atrophy
por: Fratta, Pietro, et al.
Publicado: (2014)

The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
por: Zhou, Haiyan, et al.
Publicado: (2020)

Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
por: Pera, Maria C., et al.
Publicado: (2017)

Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy
por: Lombardi, Vittoria, et al.
Publicado: (2019)

Ambulatory function in spinal muscular atrophy: Age-related patterns of progression
por: Montes, Jacqueline, et al.
Publicado: (2018)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children
por: Nitz, Elisa, et al.
Publicado: (2021)

Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy
por: Järvilehto, Julius, et al.
Publicado: (2022)

Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
por: Ramsey, Danielle, et al.
Publicado: (2017)

Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy
por: Baranello, Giovanni, et al.
Publicado: (2021)

Different trajectories in upper limb and gross motor function in spinal muscular atrophy
por: Coratti, Giorgia, et al.
Publicado: (2021)

Real-World Data on Access to Standards of Care for People With Spinal Muscular Atrophy in the UK
por: Muni-Lofra, Robert, et al.
Publicado: (2022)

Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series
por: Alves, Christiano R.R., et al.
Publicado: (2021)

Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study
por: Trucco, Federica, et al.
Publicado: (2021)

Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
por: Faravelli, Irene, et al.
Publicado: (2020)

Endoplasmic reticulum stress in spinal and bulbar muscular atrophy: a potential target for therapy
por: Montague, Karli, et al.
Publicado: (2014)

Developmental milestones in type I spinal muscular atrophy
por: De Sanctis, Roberto, et al.
Publicado: (2016)

Plasma Neurofilament Heavy Chain Levels Correlate to Markers of Late Stage Disease Progression and Treatment Response in SOD1(G93A) Mice that Model ALS
por: Lu, Ching-Hua, et al.
Publicado: (2012)

Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study
por: Li, Jin‐Yue, et al.
Publicado: (2023)

Improved Antisense Oligonucleotide Design to Suppress Aberrant SMN2 Gene Transcript Processing: Towards a Treatment for Spinal Muscular Atrophy
por: Mitrpant, Chalermchai, et al.
Publicado: (2013)

Deterioration of muscle force and contractile characteristics are early pathological events in spinal and bulbar muscular atrophy mice
por: Gray, Anna L., et al.
Publicado: (2020)

Biomarkers in Rare Disorders: The Experience with Spinal Muscular Atrophy
por: Tiziano, Francesco D., et al.
Publicado: (2010)

Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classification
por: Proud, Crystal M., et al.
Publicado: (2023)

A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
por: Paris, Alessio, et al.
Publicado: (2022)

SMN post-translational modifications in spinal muscular atrophy
por: Riboldi, Giulietta M., et al.
Publicado: (2023)

Loss of BICD2 in muscle drives motor neuron loss in a developmental form of spinal muscular atrophy
por: Rossor, Alexander M., et al.
Publicado: (2020)

In Vivo Translatome Profiling in Spinal Muscular Atrophy Reveals a Role for SMN Protein in Ribosome Biology
por: Bernabò, Paola, et al.
Publicado: (2017)

Cardiac involvement in patients with Spinal Muscular Atrophies
por: Palladino, Alberto, et al.
Publicado: (2011)

European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
por: Kirschner, Janbernd, et al.
Publicado: (2020)

Gene expression analysis reveals early dysregulation of disease pathways and links Chmp7 to pathogenesis of spinal and bulbar muscular atrophy
por: Malik, Bilal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a2uoamgaee4n1m5ucfkedpba6n